Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: LNA antisense oligonucleotides - Enzon/Roche

Drug Profile

Research programme: LNA antisense oligonucleotides - Enzon/Roche

Alternative Names: Cur 813; EZN-3889; EZN-3892; EZN-3920; EZN-4150; EZN-4482; EZN-4496; PEG-LNA-ON; SPC2004; SPC3920

Latest Information Update: 04 Nov 2017

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Santaris Pharma
  • Developer Roche
  • Class Antisense oligonucleotides
  • Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; Androgen receptor antagonists; Antisense RNA inhibitors; Beta catenin inhibitors; ERBB-3 receptor modulators; Proto-oncogene protein c-bcl-2 modulators; RNA interference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Cancer in Denmark (IV)
  • 28 Oct 2013 Enzon Pharmaceuticals terminates its licence for the research programme
  • 17 Jul 2012 Preclinical development is ongoing for cancer in the USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top